Navigation Links
Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Company's Phase III FDA Sickle Cell Treatment Trials
Date:11/19/2012

TORRANCE, Calif., Nov. 19, 2012 /PRNewswire/ -- Following a meeting on November 5, 2012 with the U.S. Food & Drug Administration (FDA), Dr. Yutaka Niihara offered the following remarks:

"The FDA's review group unanimously recommended that we proceed to complete our Phase III trial without any modification to the protocol. The trial is directed to study L-glutamine as a treatment for sickle cell disease.

"We currently have 220 patients enrolled at 32 study sites throughout the United States.  We will continue enrollment until the end of 2012, with an objective to complete the trial in 2013.

"The FDA's recommendation on proceeding to complete the trial follows the preliminary review of a subset of data from the Phase III clinical trial that was completed by an independent third party in August of this year.  Emmaus received its initial authorization from the FDA to begin the Phase III trial in August 2009, with the first patient enrolled in mid-2010.

"We continue to believe that Emmaus is the only company with a Phase III trial underway for a new sickle cell treatment.  With research grants and through the support of friends, family and private investors over the past 20 years, we have progressed to the point where we are confident in our treatment and hopeful it will be in the hands of patients worldwide in the not too distant future."

About Emmaus Medical, Inc.

Founded in 2000, Emmaus Medical, Inc. is a specialty pharmaceutical company, and subsidiary of Emmaus Life Sciences, Inc., dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases. The company is completing its Phase III clinical trial for a treatment for sickle cell disease and has entered into a collaborative agreement for the research, development and commercialization of regenerative medicine technology products. For more information, please visit www.emmausmedical.com.

Contacts:

Media:
Lori Teranishi for Emmaus Medical, Inc.
415-981-1964
lteranishi@iqprinc.com

Investors:
Roger Pondel for Emmaus Medical, Inc.
310-279-5965
rpondel@pondel.com


'/>"/>
SOURCE Emmaus Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
2. Emmaus Medical Marks Progression of Phase 3 Sickle Cell Disease Clinical Trial During Sickle Cell Awareness Month
3. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
4. Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
5. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
6. NIH Director Francis S. Collins, M.D., Ph.D. Selected as 2012 Pro Bono Humanum Honoree by Prix Galien USA
7. Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
10. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
11. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):